One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Galecto logo
Galecto GLTO
report update icon

Quarterly report 2026-Q3
added 11-04-2026

Galecto Financial Statements 2025-2011 | GLTO

Annual Financial Statements Galecto

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - 935 K 51.6 M 76.5 M 89 M - - - - - - - - -

Shares

1.36 M 1.16 M 1.06 M 25.4 M 25.3 M 7.18 M - - - - - - - - -

Historical Prices

- - 0.88 2.03 3.03 12.5 - - - - - - - - -

Net Income

-210 M -21.4 M -38.3 M -61.6 M -51.8 M -34.8 M -36.5 M -15.9 M - - - - - - -

Operating Income

-211 M -22.3 M -39.9 M -61.2 M -52.2 M -33.6 M 39 M - - - - - - - -

Interest Expense

1.17 M 844 K 1.69 M 722 K 156 K - - - - - - - - - -

EBITDA

-211 M -22.2 M -39.6 M -61.2 M -52.2 M -32.2 M -38.9 M -13.4 M - - - - - - -

Operating Expenses

211 M 22.3 M 39.9 M 61.2 M 52.2 M 33.6 M 39 M 12.9 M - - - - - - -

General and Administrative Expenses

9.68 M 10.5 M 12.7 M 13 M 13.7 M 9.01 M 2.44 M 2.81 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement Galecto

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

61.8 M 61.1 M 34.3 M 39.1 M 1.33 M 1.32 M 1.32 M 1.32 M 1.14 M 1.08 M 1.08 M 7.19 M 1.08 M 26.4 M 25.7 M 67 K 25.5 M 25.3 M 25.3 M 25.3 M 25.3 M 25.3 M 25.3 M 25.3 M 260 K 260 K 260 K 260 K 260 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-32 M -31.2 M -27.8 M -201 M -3.1 M -3.4 M -2.53 M - -3.88 M -5.34 M -5.48 M -6.48 M -8.1 M -10.7 M -13 M -14.1 M -13.7 M -16.9 M -16.9 M -13.4 M -12.7 M -12.3 M -13.3 M - -11.7 M -5.94 M -5.67 M - -4.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-36.9 M -35 M -30.8 M -202 M -3.16 M -3.42 M -2.6 M - -3.84 M -5.58 M -5.74 M -6.67 M -8.58 M -11.2 M -13.5 M -13.5 M -13.6 M -17.1 M -16.9 M -13.5 M -12.9 M -12.3 M -13.6 M - -10.2 M -6.34 M -5.83 M - 4.83 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

4.16 M 4.06 M 3.07 M 1 M 42 K 50 K 74 K - 146 K 213 K 257 K 340 K 473 K 442 K 434 K 284 K 221 K 156 K 61 K 30 K 35 K 52 K 39 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-36.9 M -35 M -30.8 M -202 M -3.15 M -3.42 M -2.59 M - -3.83 M -5.57 M -5.74 M -6.65 M -8.37 M -11.1 M -13.5 M -13.5 M -13.6 M -17.1 M -16.9 M -13.5 M -12.9 M -12.3 M -13.6 M - -10.2 M -6.34 M -5.83 M - 4.83 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

36.9 M 35 M 30.8 M 202 M 3.16 M 3.42 M 2.6 M - 3.84 M 5.58 M 5.74 M 6.67 M 8.58 M 11.2 M 13.5 M 13.5 M 13.6 M 17.1 M 16.9 M 13.5 M 12.9 M 12.3 M 13.6 M - 10.2 M 6.34 M 5.83 M - 4.83 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

11.4 M 9.45 M 7.03 M 4.07 M 1.74 M 1.96 M 1.92 M - 2.75 M 2.78 M 3.28 M 3.18 M 3.3 M 3.07 M 3.13 M 2.76 M 3.13 M 3.41 M 3.7 M 3.35 M 3.19 M 3.63 M 3.56 M - 2.52 M 1.82 M 1.12 M - 1.15 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Galecto GLTO
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Galecto plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 4.33 3.34 % $ 672 M usaUSA
AbbVie AbbVie
ABBV
$ 294.7 3.04 % $ 521 B usaUSA
Amgen Amgen
AMGN
$ 478.61 3.76 % $ 257 B usaUSA
Geron Corporation Geron Corporation
GERN
$ 1.07 15.32 % $ 713 M usaUSA
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 0.65 4.82 % $ 39 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 160.93 0.65 % $ 21.1 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.12 -2.96 % $ 259 M usaUSA
Merck & Co. Merck & Co.
MRK
$ 150.29 3.88 % $ 376 B usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 0.87 0.78 % $ 58.2 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.36 -1.36 % $ 2.83 M israelIsrael
Ocugen Ocugen
OCGN
$ 0.87 17.34 % $ 272 M usaUSA
Revolution Medicines Revolution Medicines
RVMD
$ 199.48 2.7 % $ 37.9 B usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
- -3.76 % $ 3.47 M usaUSA
BioVie BioVie
BIVI
$ 1.32 -23.7 % $ 1.95 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Gossamer Bio Gossamer Bio
GOSS
$ 9.95 7.22 % $ 2.27 B usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
$ 51.05 4.83 % $ 207 B britainBritain
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 608.19 1.14 % $ 26.9 B usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.42 -12.65 % $ 95.5 M germanyGermany
Immunome Immunome
IMNM
$ 19.54 -3.79 % $ 1.71 B usaUSA
Immatics N.V. Immatics N.V.
IMTX
$ 6.9 -2.47 % $ 844 M germanyGermany
Incyte Corporation Incyte Corporation
INCY
$ 122.89 4.51 % $ 24 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
$ 109.95 5.28 % $ 21.9 B usaUSA
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
$ 8.72 -1.25 % $ 3.12 M usaUSA
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
$ 3.75 7.0 % $ 607 M usaUSA
Jaguar Health Jaguar Health
JAGX
$ 0.5 -10.33 % $ 1.17 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA